ZURA

Zura Bio Limited (ZURA) | Rumor.io

Zura Bio

ZURA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,330

Bullish sentiment (50-day avg)64%

Price to earnings ratio7.95

Market capitalization392.9M

Earnings per share-1.12

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-68.7M

Social

What share of all stock conversation is about ZURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jan 21

Zura Bio Limited's ($ZURA) stock price surged 15.3% after the company announced the expansion of its Phase 2 TibuSHIELD trial for hidradenitis suppurativa.
Sandeep Kulkarni, M.D., has been appointed as the new Chief Executive Officer of Zura Bio Limited, effective January 21, 2026, bringing over 20 years of experience in biotechnology and medicine.
Zura Bio Limited is developing tibulizumab, a bispecific antibody targeting IL-17 and BAFF pathways for autoimmune diseases, with two potentially transformative data readouts expected over the next 18 months.

Generated by AI

Sentiment

Of the messages about ZURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	52.05% -47.95	89.87% +7.37
Bearish	—	—	47.95% +47.95	10.13% -7.37

Bullish· Sep 30

$ZURA has shown significant gains, surging 93% and reaching a high of $5.07, indicating further upside potential.
The stock has strong technical indicators, including a possible falling wedge on the chart and volume picking up, suggesting a continuation of the upward trend.
Chardan Capital raised its price target to $10, which could lead to a big squeeze for shorts and a potential multi-bagger opportunity for investors.

Bearish· Sep 30

$ZURA is predicted to drop to $3.80 by Friday, with a short sell limit order set at $4.31.
The stock's recent price action is seen as a "pump and dump" scheme, with a warning to short the asset.
A potential drop to $2.50 is anticipated, with a warning to sell and short the stock.

Generated by AI

Topics

Of the messages about ZURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	17.39%	67.64%
Technical Analysis	—	—	41.3%	24.76%
Controversies	—	—	41.3%	3.4%
Analysts	—	—	0%	4.21%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jun 6

Zura Bio Limited completed a private placement resulting in gross proceeds of approximately $80 million, which will be used to fund clinical trials for its potential first-in-class dual antagonist ZB-106.
The financing deal will enable Zura Bio to proceed with its planned Phase 2 clinical trials for ZB-106, a potential treatment for immune-mediated diseases.
Zura Bio has raised a total of $120 million in cash, which will fund the company's operations through 2026, including the development of two Phase 2 trials for ZB-106.

Technical Analysis· Sep 30

$ZURA has been in a strong uptrend, breaking through fib levels and extending above 0.236 at $4.18, with heavy volume and a possible bull flag formation.
The stock is showing signs of consolidation above VWAP, with some traders waiting for a pullback or reversal near $3.80 or a rejection off the 4.20 level.
Technical indicators such as RSI and volume are indicating strong momentum, with some traders targeting further price increases to $4.50 or above, but others setting stop-losses at lower levels.

Generated by AI

Community

Of the messages about ZURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	77.78%	55.26%
Newcomers	100%	100%	22.22%	44.74%

Dec 29

The newcomer users are focused on the stock's recent price surge, with one user attributing the +12% increase to a potential "window dressing" by funds before the end of Q4.
Some users are recommending the stock, setting targets at $8.2, and suggesting a 2:1 risk-to-reward trade with a stop-loss at $4.47.
The users are also discussing the stock's technical analysis, including a confirmed breakout at $5.40, a technical target at $6.61, and a momentum fueled by the Q3 financial results update.

Generated by AI

On August 11, Zura Bio (NASDAQ:ZURA) reported second-quarter results that landed on an unusual mix of good and bad news. The clinical-stage biotech finished enrolling two separate Phase 2 studies of its lead drug, tibulizumab, both ahead of their original targets, while a widening net loss showed just how much it costs to run them. […]

19d agoYahoo Finance

Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead

20d agoInvesting.com

Zura Bio to Participate in the Cantor Global Healthcare Conference

HENDERSON, Nev., August 31, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference:

29d agoYahoo Finance

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev., August 21, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the "Options") to thirteen newly hired employees. These a

1mo agoYahoo Finance

Guggenheim raises Zura Bio stock price target on new drug indication

1mo agoInvesting.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

HENDERSON, Nev., August 11, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided recent corporate updates.

1mo agoYahoo Finance

Also Discussed

Investors talking about ZURA also mention

#	Name	Attention
1	Ambipar Emergency Response Inc.AMBI	0%new
2	Pyxis Oncology, Inc. Common StockPYXS	0%0
3	LSB - LakeShore Biopharma Co., Ltd	——
4	UHG - United Homes Group, Inc.	——
5	HPX - HPX Corp.	——
6	INKA - KludeIn I Acquisition Corp.	——
7	AEHA - Aesther Healthcare Acquisition Corp.	——
8	SAI - SAI.TECH Global Corporation	——
9	SunCar Technology Group Inc. Class A Ordinary SharesSDA	0%0
10	Apollomics Inc.APLM	0%0

Zura Bio Limited

Healthcare
Biotechnology

Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. The company is building a multi-asset immunology pipeline centered on dual-pathway antibodies designed to address immune system imbalance and improve treatment options for patients with serious, underserved conditions. Its current programs include tibulizumab, torudokimab, and crebankitug, each targeting distinct immune pathways involved in inflammation and autoimmune activity. Zura Bio Limited concentrates on therapeutic areas such as hidradenitis suppurativa, systemic sclerosis, alopecia areata, and other immune-mediated disorders. By advancing differentiated antibody-based therapies, the company plays a specialized role in the biotechnology market as a developer of precision treatments for complex inflammatory diseases. Zura Bio Limited is headquartered in Henderson, Nevada.

Website

Location

1489 W. Warm Springs Road

Henderson, NV, 89014

United States

Social

What share of all stock conversation is about ZURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jan 21

Zura Bio Limited's ($ZURA) stock price surged 15.3% after the company announced the expansion of its Phase 2 TibuSHIELD trial for hidradenitis suppurativa.
Sandeep Kulkarni, M.D., has been appointed as the new Chief Executive Officer of Zura Bio Limited, effective January 21, 2026, bringing over 20 years of experience in biotechnology and medicine.
Zura Bio Limited is developing tibulizumab, a bispecific antibody targeting IL-17 and BAFF pathways for autoimmune diseases, with two potentially transformative data readouts expected over the next 18 months.

Generated by AI

Sentiment

Of the messages about ZURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	52.05% -47.95	89.87% +7.37
Bearish	—	—	47.95% +47.95	10.13% -7.37

Bullish· Sep 30

$ZURA has shown significant gains, surging 93% and reaching a high of $5.07, indicating further upside potential.
The stock has strong technical indicators, including a possible falling wedge on the chart and volume picking up, suggesting a continuation of the upward trend.
Chardan Capital raised its price target to $10, which could lead to a big squeeze for shorts and a potential multi-bagger opportunity for investors.

Bearish· Sep 30

$ZURA is predicted to drop to $3.80 by Friday, with a short sell limit order set at $4.31.
The stock's recent price action is seen as a "pump and dump" scheme, with a warning to short the asset.
A potential drop to $2.50 is anticipated, with a warning to sell and short the stock.

Generated by AI

Topics

Of the messages about ZURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	17.39%	67.64%
Technical Analysis	—	—	41.3%	24.76%
Controversies	—	—	41.3%	3.4%
Analysts	—	—	0%	4.21%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Jun 6

Zura Bio Limited completed a private placement resulting in gross proceeds of approximately $80 million, which will be used to fund clinical trials for its potential first-in-class dual antagonist ZB-106.
The financing deal will enable Zura Bio to proceed with its planned Phase 2 clinical trials for ZB-106, a potential treatment for immune-mediated diseases.
Zura Bio has raised a total of $120 million in cash, which will fund the company's operations through 2026, including the development of two Phase 2 trials for ZB-106.

Technical Analysis· Sep 30

$ZURA has been in a strong uptrend, breaking through fib levels and extending above 0.236 at $4.18, with heavy volume and a possible bull flag formation.
The stock is showing signs of consolidation above VWAP, with some traders waiting for a pullback or reversal near $3.80 or a rejection off the 4.20 level.
Technical indicators such as RSI and volume are indicating strong momentum, with some traders targeting further price increases to $4.50 or above, but others setting stop-losses at lower levels.

Generated by AI

Community

Of the messages about ZURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	77.78%	55.26%
Newcomers	100%	100%	22.22%	44.74%

Dec 29

The newcomer users are focused on the stock's recent price surge, with one user attributing the +12% increase to a potential "window dressing" by funds before the end of Q4.
Some users are recommending the stock, setting targets at $8.2, and suggesting a 2:1 risk-to-reward trade with a stop-loss at $4.47.
The users are also discussing the stock's technical analysis, including a confirmed breakout at $5.40, a technical target at $6.61, and a momentum fueled by the Q3 financial results update.

Generated by AI

Zura Bio

Social

Jan 21

Sentiment

Bullish· Sep 30

Bearish· Sep 30

Topics

Announcements· Jun 6

Technical Analysis· Sep 30

Community

Dec 29

News

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead

Zura Bio to Participate in the Cantor Global Healthcare Conference

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guggenheim raises Zura Bio stock price target on new drug indication

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Also Discussed

Zura Bio Limited

Company Information

Location

News

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

Zura Bio at 12th annual cantor fitzgerald global healthcare conference: data ahead

Zura Bio to Participate in the Cantor Global Healthcare Conference

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guggenheim raises Zura Bio stock price target on new drug indication

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Also Discussed

Social

Jan 21

Sentiment

Bullish· Sep 30

Bearish· Sep 30

Topics

Announcements· Jun 6

Technical Analysis· Sep 30

Community

Dec 29